Cargando…

Diagnosis and management of microscopic colitis: current perspectives

Collagenous colitis and lymphocytic colitis, together constituting microscopic colitis, are common causes of chronic diarrhea. They are characterized clinically by chronic nonbloody diarrhea and a macroscopically normal colonic mucosa where characteristic histopathological findings are seen. Previou...

Descripción completa

Detalles Bibliográficos
Autores principales: Bohr, Johan, Wickbom, Anna, Hegedus, Agnes, Nyhlin, Nils, Hultgren Hörnquist, Elisabeth, Tysk, Curt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144984/
https://www.ncbi.nlm.nih.gov/pubmed/25170275
http://dx.doi.org/10.2147/CEG.S63905
_version_ 1782332112816308224
author Bohr, Johan
Wickbom, Anna
Hegedus, Agnes
Nyhlin, Nils
Hultgren Hörnquist, Elisabeth
Tysk, Curt
author_facet Bohr, Johan
Wickbom, Anna
Hegedus, Agnes
Nyhlin, Nils
Hultgren Hörnquist, Elisabeth
Tysk, Curt
author_sort Bohr, Johan
collection PubMed
description Collagenous colitis and lymphocytic colitis, together constituting microscopic colitis, are common causes of chronic diarrhea. They are characterized clinically by chronic nonbloody diarrhea and a macroscopically normal colonic mucosa where characteristic histopathological findings are seen. Previously considered rare, they now have emerged as common disorders that need to be considered in the investigation of the patient with chronic diarrhea. The annual incidence of each disorder is five to ten per 100,000 inhabitants, with a peak incidence in 60- to 70-year-old individuals and a predominance of female patients in collagenous colitis. The etiology and pathophysiology are not well understood, and the current view suggests an uncontrolled mucosal immune reaction to various luminal agents in predisposed individuals. Clinical symptoms comprise chronic diarrhea, abdominal pain, fatigue, weight loss, and fecal incontinence that may impair the patient’s health-related quality of life. An association is reported with other autoimmune disorders, such as celiac disease, thyroid disorders, diabetes mellitus, and arthritis. The best-documented treatment, both short-term and long-term, is budesonide, which induces clinical remission in up to 80% of patients after 8 weeks’ treatment. However, after successful budesonide therapy is ended, recurrence of clinical symptoms is common, and the best possible long-term management deserves further study. The long-term prognosis is good, and the risk of complications, including colonic cancer, is low. We present an update of the epidemiology, pathogenesis, diagnosis, and management of microscopic colitis.
format Online
Article
Text
id pubmed-4144984
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-41449842014-08-28 Diagnosis and management of microscopic colitis: current perspectives Bohr, Johan Wickbom, Anna Hegedus, Agnes Nyhlin, Nils Hultgren Hörnquist, Elisabeth Tysk, Curt Clin Exp Gastroenterol Review Collagenous colitis and lymphocytic colitis, together constituting microscopic colitis, are common causes of chronic diarrhea. They are characterized clinically by chronic nonbloody diarrhea and a macroscopically normal colonic mucosa where characteristic histopathological findings are seen. Previously considered rare, they now have emerged as common disorders that need to be considered in the investigation of the patient with chronic diarrhea. The annual incidence of each disorder is five to ten per 100,000 inhabitants, with a peak incidence in 60- to 70-year-old individuals and a predominance of female patients in collagenous colitis. The etiology and pathophysiology are not well understood, and the current view suggests an uncontrolled mucosal immune reaction to various luminal agents in predisposed individuals. Clinical symptoms comprise chronic diarrhea, abdominal pain, fatigue, weight loss, and fecal incontinence that may impair the patient’s health-related quality of life. An association is reported with other autoimmune disorders, such as celiac disease, thyroid disorders, diabetes mellitus, and arthritis. The best-documented treatment, both short-term and long-term, is budesonide, which induces clinical remission in up to 80% of patients after 8 weeks’ treatment. However, after successful budesonide therapy is ended, recurrence of clinical symptoms is common, and the best possible long-term management deserves further study. The long-term prognosis is good, and the risk of complications, including colonic cancer, is low. We present an update of the epidemiology, pathogenesis, diagnosis, and management of microscopic colitis. Dove Medical Press 2014-08-21 /pmc/articles/PMC4144984/ /pubmed/25170275 http://dx.doi.org/10.2147/CEG.S63905 Text en © 2014 Bohr et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Bohr, Johan
Wickbom, Anna
Hegedus, Agnes
Nyhlin, Nils
Hultgren Hörnquist, Elisabeth
Tysk, Curt
Diagnosis and management of microscopic colitis: current perspectives
title Diagnosis and management of microscopic colitis: current perspectives
title_full Diagnosis and management of microscopic colitis: current perspectives
title_fullStr Diagnosis and management of microscopic colitis: current perspectives
title_full_unstemmed Diagnosis and management of microscopic colitis: current perspectives
title_short Diagnosis and management of microscopic colitis: current perspectives
title_sort diagnosis and management of microscopic colitis: current perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144984/
https://www.ncbi.nlm.nih.gov/pubmed/25170275
http://dx.doi.org/10.2147/CEG.S63905
work_keys_str_mv AT bohrjohan diagnosisandmanagementofmicroscopiccolitiscurrentperspectives
AT wickbomanna diagnosisandmanagementofmicroscopiccolitiscurrentperspectives
AT hegedusagnes diagnosisandmanagementofmicroscopiccolitiscurrentperspectives
AT nyhlinnils diagnosisandmanagementofmicroscopiccolitiscurrentperspectives
AT hultgrenhornquistelisabeth diagnosisandmanagementofmicroscopiccolitiscurrentperspectives
AT tyskcurt diagnosisandmanagementofmicroscopiccolitiscurrentperspectives